KRAS and lung carcinoma: Direct evidence supporting the role of vimentin in the migration of Kras-mutant, Tp53-null lung cancer cells was demonstrated by disrupting vimentin expression genetically (Fig. 3A) and pharmacologically in mouse- (Fig. 3E) and human-derived (Supplementary Fig. S3C) cancer cells resulting in impaired migration.